524 related articles for article (PubMed ID: 22013117)
1. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.
Hossain MS; Jaye DL; Pollack BP; Farris AB; Tselanyane ML; David E; Roback JD; Gewirtz AT; Waller EK
J Immunol; 2011 Nov; 187(10):5130-40. PubMed ID: 22013117
[TBL] [Abstract][Full Text] [Related]
2. [Prophylactic effect of TLR5 agonist flagellin on acute graft versus host disease after allogeneic hematopoietic stem cell transplantation and its mechanism].
Gong XD; Ma LM; Zhu L; Guo HM; Ren LS; Ren RR; Zhang HP; Wei F; Niu YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):965-70. PubMed ID: 22931665
[TBL] [Abstract][Full Text] [Related]
3. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK
J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114
[TBL] [Abstract][Full Text] [Related]
5. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
6. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.
Palaniyandi S; Radhakrishnan SV; Karlsson FJ; Stokes KY; Kittan N; Huber E; Hildebrandt GC
PLoS One; 2013; 8(4):e61841. PubMed ID: 23596528
[TBL] [Abstract][Full Text] [Related]
7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.
Fricke S; Rothe K; Hilger N; Ackermann M; Oelkrug C; Fricke C; Schönfelder U; Niederwieser D; Emmrich F; Sack U
Cytometry A; 2012 Jun; 81(6):476-88. PubMed ID: 22522779
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
10. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.
Hossain MS; Ramachandiran S; Gewirtz AT; Waller EK
PLoS One; 2014; 9(5):e96165. PubMed ID: 24879439
[TBL] [Abstract][Full Text] [Related]
11. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.
Spilleboudt C; De Wilde V; Lewalle P; Cabanne L; Leclerc M; Beckerich F; Bories D; Cardoso S; Soares MP; Vokaer B; Hougardy JM; Flamand V; Racapé J; Abramowicz M; Maury S; Le Moine A
Front Immunol; 2020; 11():579151. PubMed ID: 33537027
[TBL] [Abstract][Full Text] [Related]
12. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
Wang J; Li L; Xu M; Rong R; Zhu T
Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
14. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.
Ross D; Jones M; Komanduri K; Levy RB
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1430-8. PubMed ID: 23819914
[TBL] [Abstract][Full Text] [Related]
15. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
[TBL] [Abstract][Full Text] [Related]
16. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.
Nguyen VH; Shashidhar S; Chang DS; Ho L; Kambham N; Bachmann M; Brown JM; Negrin RS
Blood; 2008 Jan; 111(2):945-53. PubMed ID: 17916743
[TBL] [Abstract][Full Text] [Related]
17. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.
Wang H; Asavaroengchai W; Yeap BY; Wang MG; Wang S; Sykes M; Yang YG
Blood; 2009 Apr; 113(15):3612-9. PubMed ID: 19211507
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
20. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
